

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

Olerup SSP® HLA-A low resolution

Product number:	101.401-48/12 – including <i>Taq</i> polymerase 101.401-48u/12u – without <i>Taq</i> polymerase
Lot number:	9R2
Expiry date:	2027-03-01
Number of tests:	48 tests – Product No. 101.401-48/48u 12 tests – Product No. 101.401-12/12u
Number of wells per test:	31+1
Storage - pre-aliquoted primers:	dark, between -15°C and -25°C
- PCR Master Mix:	between -15°C and -25°C
- Adhesive PCR seals	RT

This Product Description is only valid for Lot No. 9R2.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-A LOW RESOLUTION LOT (3R0)

The HLA-A low resolution specificity and interpretation tables have been updated for the HLA-A alleles reported since the previous *Olerup SSP®* HLA-A low resolution lot was made (**Lot No. 3R0**). The kit design is based on IMGT/HLA database 3.51.0.

The primers of the wells detailed below have been exchanged, modified or added compared to the previous lot.

Well	5'-primer	3'-primer	rationale
2	Added	-	5'-primer added for the A*02:01:207 allele.
19	Added, removed	-	5'-primer added for the A*74:41 allele. 2 5'-primers removed.

Changes in revision R01 compared to R00:

1. Primer mix 27 does not amplify the A*03:69N allele. This has been corrected in the Product Insert and the Worksheet.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

Well **32** contains Negative Control primer pairs, that will amplify the majority of the *Olerup* SSP® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the positive control primer pairs is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
5'-primer¹	164	340	440	45	45	43	36
	5'-CAC3'	5'-Agg3'	5'-TTA3'	5'-Tgg3'	5'-Tgg3'	5'-Tgg3'	5'-TAC3'
							36
							5'-TAT3'
3'-primer²	231	2nd I	507	59	58	57	47
	5'-TgC3'	5'-AAA3'	5'-TTg3'	5'-CTC3'	5'-ggC3'	5'-CTC3'	5'-ACA3'
							48
							5'-gCA3'
							48
							5'-gCC3'
							52
							5'-TgT3'
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

PRODUCT DESCRIPTION

HLA-A low resolution

CONTENT

The primer set contains 5'- and 3'-primers for grouping the HLA-A*01:01 to A*80:09N alleles into the corresponding serological groups A1 to A80.

PLATE LAYOUT

Each test consists of 32 PCR reactions in a 32 well PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	NC

The 32 well PCR plate is marked with 'HLA-A low' in silver/gray ink.

Well No. 1 is marked with the Lot No. '9R2'.

Wells 1 to 31 – HLA-A low resolution primers.

Well 32 – Negative Control.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

Please note: When removing each 32 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

Only HLA-A alleles will be amplified by the 32 wells of the HLA-A low resolution primer set, **wells 1 to 31**, except that a few HLA-B and HLA-C alleles will be amplified by some primer mixes. For further details see Specificity Table.

UNIQUELY IDENTIFIED ALLELES

All the HLA-A alleles, i.e. **A*01:01 to A*80:09N**, recognized by the HLA Nomenclature Committee in January 2023^{1,2} will be amplified by the primers in the HLA-A low resolution primer set³. The HLA-A alleles will be grouped into their corresponding serological specificities.



0197

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

¹HLA-A alleles listed on the IMGT/HLA web page 2023-January-12, release 3.51.0, www.ebi.ac.uk/imgt/hla.

²Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

³The following alleles give rise to identical amplification patterns with the HLA-A low resolution primer set. These alleles can be separated by the respective high-resolution primer sets.

Alleles	Alleles
A*01:427, 36:02	A*25:78, 26:57, 66:15
A*11:325, 24:555	A*30:12:01-30:12:02, 30:31, 30:152, 30:166, B*07:260, C*12:328
A*23:14:01-23:14:02, 23:104-23:105, 24:71, 24:315, 24:392, 24:527	A*31:08, 33:53
A*23:66, 23:99, 23:128, 24:14:01:01-24:15, 24:51-24:53, 24:57, 24:64, 24:94, 24:114, 24:138, 24:188, 24:222N, 24:228, 24:291, 24:296, 24:304, 24:316, 24:324, 24:412, 24:481, 24:515, B*53:72, C*04:01:03	A*34:06, 66:40



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

SPECIFICITY TABLE

HLA-A low resolution primer set

Specificities and sizes of the PCR products of the 31+1 primer mixes used for HLA-A low resolution SSP typing

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	HLA-A serology ³	Amplified HLA-A alleles ⁴
1⁵	120 bp, 145 bp	800 bp	A1, A36	*01:01:01:01-01:01:31, 01:01:33-01:01:59, 01:01:61-01:04:01:02N, 01:06-01:33, 01:35-01:68, 01:70-01:142, 01:144-01:170, 01:172-01:187, 01:189-01:219, 01:221-01:306, 01:308N-01:341, 01:343-01:400N, 01:402-01:427, 03:395, 11:282, 26:120, 32:156, 36:01:01:01-36:13
2	135 bp, 175 bp, 215 bp, 255 bp, 365 bp, 415 bp	800 bp	A2, A19, A28, A203, A210	*02:01:01:01-02:01:07, 02:01:09-02:01:15, 02:01:17-02:01:19, 02:01:21-02:01:81, 02:01:83-02:22:02, 02:24:01-02:35:01, 02:35:03-02:47, 02:49:01-02:77, 02:78 ^w , 02:79:01-02:97:02, 02:99:01-02:99:02, 02:101:01-02:128, 02:130-02:570:02, 02:572-02:643N, 02:645-02:828, 02:830:01-02:1089, 03:89:01, 30:13, 30:16, 30:22, 30:44, 30:46, B*35:01:60^w, B*58:01:24^w
3	235 bp	1070 bp	A3, A32, A36	*01:427, 03:01:01:01-03:01:29, 03:01:31-03:01:34, 03:01:36-03:01:48, 03:01:51-03:01:89, 03:01:91-03:01:105, 03:01:107-03:04:03, 03:06-03:09, 03:11N-03:17:02, 03:19-03:39, 03:41, 03:43-03:74, 03:76-03:94, 03:96-03:97, 03:99-03:104, 03:106-03:121, 03:123:01-03:134, 03:136-03:166, 03:168N-03:176, 03:178N-03:186, 03:188-03:193, 03:195-03:199, 03:201-03:203, 03:205-03:207, 03:209-03:214, 03:216-03:224, 03:226-03:259, 03:261-03:325, 03:327-03:331, 03:333-03:342N, 03:344:01-03:346, 03:348-03:413, 03:415-03:451, 03:453-03:458Q, 11:130, 30:89, 32:04, 36:02
4	190 bp	800 bp	A1, A3, A11, A30, A36, A68	*01:01:01:01-01:01:22, 01:01:24-01:01:47, 01:01:49-01:01:64, 01:01:67-01:01:78, 01:01:80-01:04:01:02N, 01:06-01:07, 01:09:01:01-01:11N, 01:13, 01:15N ^w , 01:16N-01:18N, 01:20-01:29, 01:31N-01:33, 01:35-01:78, 01:80-01:98, 01:100-01:144, 01:146, 01:148, 01:150-01:158, 01:160N-01:166, 01:168-01:177, 01:179N-01:199, 01:201-01:204, 01:206-01:207, 01:209-01:213, 01:215-01:227, 01:229-01:235, 01:237-01:243, 01:245-01:266:02, 01:268-01:270, 01:272-01:278, 01:280-01:313, 01:315-01:375, 01:377-01:390, 01:392-01:395, 01:397-01:402, 01:404-01:417N, 01:419-01:426, 02:78, 02:169, 02:829, 03:12, 03:18, 03:88, 03:135, 11:01:01:01-11:27,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

				11:29-11:52Q, 11:54:01-11:438, 24:555, 25:43, 25:59, 26:19, 26:72, 26:184, 26:204:01:01-26:204:01:02, 29:67, 29:156, 30:08:01-30:08:02, 30:150, 32:64, 34:19, 36:04, 66:23, 68:13:01, 68:66:01-68:66:02, 68:134, 68:178, 74:19, C*03:365, C*12:131
5	160 bp, 335 bp, 505 bp	1070 bp	A3, A9, A23, A24, A2403, A29, A31, A32	*01:301Q, 03:15, 03:19, 03:30, 03:152, 03:273, 03:347, 11:139, 11:325, 23:01:01:01-23:68, 23:70-23:112, 23:114-23:129, 24:02:01:01-24:11N, 24:13:01-24:15, 24:17:01:01-24:64, 24:66-24:210, 24:212-24:470, 24:472-24:589, 25:81-25:82, 29:07, 29:49, 31:08, 31:29, 32:05, 32:72, 32:170, 33:19, 33:53, 33:187, 68:249, B*53:72, C*04:01:03
6^{6,10}	135 bp, 200 bp	800 bp	A9, A23, A24, A29, A80	*23:01:01:01-23:56, 23:58-23:65, 23:67-23:68, 23:70-23:98, 23:100-23:112, 23:114-23:127, 23:129, 24:24, 24:71, 24:315, 24:392, 24:527, 24:569, 29:07, 29:49, 31:29, 31:85, 32:72, 32:170, 33:187, 80:01:01:01-80:09N, B*18:27
7	175 bp, 205 bp	1070 bp	A2, A3, A9, A23, A24, A2403, A26	*01:301Q, 02:17:02:01 ^w -02:17:04 ^w , 02:804, 03:347, 11:139, 23:14:01-23:14:02, 23:104-23:105, 24:02:01:01-24:11N, 24:13:01-24:13:02, 24:17:01:01-24:50, 24:54-24:56:02, 24:58-24:63, 24:66-24:91, 24:93, 24:95-24:113, 24:115-24:137, 24:139-24:187, 24:189-24:210, 24:212-24:221, 24:223-24:227, 24:229-24:290, 24:292-24:295, 24:297-24:303N, 24:305-24:315, 24:317-24:323N, 24:325-24:411, 24:413-24:457, 24:459:01-24:470, 24:472-24:480, 24:482-24:514N, 24:516-24:550, 24:552-24:554, 24:556N, 24:558-24:573, 24:575-24:589, 26:16, 30:163, 33:19, 33:119, 68:45, 68:117
8	165 bp, 200 bp	800 bp	A2/A28, A3, A10, A11, A25, A26, A32, A34, A66, A68, A69	*01:51, 01:344, 01:381, 02:55, 02:527, 02:582, 02:644, 02:741, 02:815, 03:24, 03:50, 11:10, 11:183, 11:191, 11:269, 25:01:01:01-25:16, 25:18-25:33, 25:35-25:45, 25:47-25:53, 25:55-25:58, 25:60-25:70, 25:72-25:76:02, 25:78-25:80, 25:84, 26:01:01:01-26:01:47, 26:01:49-26:03:01:02, 26:03:03-26:06, 26:08:01:01-26:15, 26:17-26:18, 26:20:01-26:43:02, 26:45-26:63, 26:65-26:71N, 26:73-26:88, 26:90-26:91, 26:93-26:176, 26:178-26:183, 26:185-26:206:02N, 26:208-26:229, 29:28, 32:15, 33:51, 34:01:01:01-34:18, 34:20-34:30N, 66:01:01:01-66:22, 66:24-66:41, 66:43-66:47, 68:01:01:01-68:177, 68:179-68:249, 68:251N-68:298, 69:01:01:01-69:09
9^{5,7}	80 bp	800 bp	A2, A3, A25, A32, B53	*01:298, 02:81, 02:124, 02:829, 25:01:01:01-25:45, 25:47-25:58, 25:60-25:76:02, 25:79-25:80, 25:83-25:84, 32:01:01:01-32:02, 32:04, 32:06-32:37, 32:39-32:59, 32:61-32:70, 32:72-32:77, 32:81-32:106:01:02, 32:108-32:173, B*07:81, B*08:52, B*18:67, B*38:41, B*38:67, B*49:67,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

B*51:185, B*53:05:01-53:05:02, B*53:16, B*53:33, B*57:01:38, B*57:60				
10^{5,10}	80 bp, 200 bp, 240 bp	800 bp	A10, A26, A43	*01:43, 01:51, 02:644, 11:17, 11:40, 11:223, 11:271, 25:59, 26:01:01:01-26:02:02, 26:04, 26:07:01-26:20:02, 26:22-26:29, 26:31-26:43:02, 26:45-26:56, 26:58-26:77, 26:79-26:91, 26:93- 26:110, 26:112:01-26:176, 26:178-26:226, 26:228, 29:105, 29:164, 33:13, 33:48, 43:01-43:03, 68:84, 68:227
11⁵	80 bp, 175 bp, 500 bp	1070 bp	A1, A9, A10, A11, A26, A34, A66	*01:13, 01:26, 01:28, 01:136, 01:176, 01:192, 01:229, 01:299, 01:380:01:01-01:380:01:02, 03:63, 03:88, 11:01:01:01-11:27, 11:29-11:52Q, 11:54:01-11:270, 11:272Q-11:438, 24:19, 24:44, 24:555, 26:03:01:01-26:03:01:02, 26:03:03, 26:06, 26:21, 26:78, 26:92, 26:111, 26:152, 26:177, 26:193, 26:229, 30:125, 30:140, 33:184, 34:01:01:01-34:08, 34:10N-34:30N, 66:01:01:01- 66:01:07, 66:04-66:11, 66:13-66:14, 66:17-66:20, 66:22-66:24, 66:27N, 66:29-66:33, 66:35-66:38, 66:40-66:42, 66:44-66:47, 68:271, 69:02, 74:30, 80:02
12⁵	125 bp, 160 bp, 190 bp	800 bp	A10, A25, A26, A31, A34, A43, A66	*01:01:56, 01:361N, 02:309, 02:454, 03:01:19, 03:103:02, 11:11, 25:05-25:06, 26:09, 26:54, 26:91, 26:217, 26:229, 31:03-31:04:02, 31:123, 34:01:01:01-34:30N, 43:01-43:03, 66:02:01:01- 66:03:01:03, 66:16, 66:19, 66:21, 66:25-66:26Q, 66:28N, 66:34, 66:39N-66:40, 66:43, 68:130:01, 68:294, 74:01:03
13¹¹	180 bp, 225 bp	1070 bp	A1, A2, A3, A10, A25, A26, A34, A43, A66	*01:13, 01:176, 01:194, 02:34-02:35:03, 02:56:01- 02:56:02, 02:62, 02:103, 02:135, 02:580, 02:741, 02:907, 03:01:01:01-03:01:22, 03:01:24-03:01:82, 03:01:84-03:01:93, 03:01:95-03:07:02, 03:09- 03:11N, 03:13-03:31, 03:33-03:35, 03:37-03:40, 03:42-03:56:01:02, 03:58, 03:60-03:71, 03:73- 03:87, 03:90-03:106, 03:109-03:110, 03:112- 03:141, 03:143-03:151, 03:153-03:171, 03:174- 03:175, 03:177, 03:179-03:193, 03:195- 03:197:02N, 03:201-03:202, 03:204, 03:206- 03:210, 03:212-03:218, 03:220-03:251, 03:253- 03:259, 03:261-03:266N, 03:268-03:272, 03:274- 03:329N, 03:331-03:381N, 03:383-03:397, 03:399-03:412, 03:414-03:428, 03:430-03:458Q, 11:116, 11:140, 11:199:01-11:199:03, 11:222, 25:01:01:01-25:05, 25:07-25:35, 25:37-25:42N, 25:44-25:49N, 25:51, 25:53-25:58, 25:60-25:64, 25:66-25:84, 26:01:01:01-26:01:78, 26:02:01 ^w - 26:02:02 ^w , 26:03:01:01-26:03:01:02, 26:03:03, 26:05-26:08:03, 26:10-26:28, 26:29 ^w , 26:30- 26:43:02, 26:45-26:48, 26:49 ^w , 26:50-26:74, 26:76-26:77, 26:79-26:90, 26:92-26:203, 26:206:01N-26:229, 30:55, 30:186, 31:24-31:25, 32:26:01-32:26:02, 32:152, 33:61, 33:190, 34:08, 43:01-43:03, 66:01:01:01-66:01:07, 66:04-66:09, 66:10 ^w , 66:11-66:15, 66:17-66:20, 66:22-66:24,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

				66:27N, 66:29-66:33, 66:35-66:38, 66:41-66:42, 66:44-66:47, 68:71, 69:07, 74:13, 74:37
14^{5,10}	80 bp, 115 bp, 200 bp, 240 bp, 460 bp	1070 bp	A26, A29, A31, A34, A36, A68	*01:427, 02:237, 02:309, 02:454, 02:809, 02:927, 03:01:38, 03:95, 03:123:02, 03:171, 03:231:01, 03:343, 03:428, 11:130, 26:19, 26:22, 26:198, 29:01:01:01-29:172, 31:03-31:04:02, 31:123, 32:42, 34:04, 36:02, 66:09, 68:19, 68:130:02
15^{5,9,11}	90 bp, 135 bp, 205 bp	1070 bp	A1, A30	*01:13, 01:28, 01:176, 01:194, 01:229, 01:299, 03:43, 03:82, 03:186, 03:395, 11:113, 11:162, 11:282, 30:01:01:01-30:04:04, 30:06-30:20, 30:22-30:206, 31:35, B*07:260, C*12:328
16	145 bp, 240 bp, 380 bp, 410 bp	1070 bp	A24, A31, A32	*02:237, 02:809, 02:927, 03:95, 03:343, 11:306, 23:11N, 24:586N, 29:14, 29:172, 31:01:02:01-31:219, 32:05, 32:79, 32:128, 33:53, 33:125, 33:131, 74:13, 74:44
17¹¹	140 bp, 180 bp, 240 bp, 260 bp	1070 bp	A1, A3, A25, A32, A74	*01:07, 01:95, 01:289, 01:298, 03:32, 03:43, 03:82, 03:152, 03:186, 03:219, 03:273, 03:429, 23:64, 24:104, 24:243, 25:03, 25:30, 29:13, 29:39, 29:98, 30:89, 30:177, 31:21, 31:35, 32:01:01:01-32:173, 74:07, 74:33, 80:04, B*15:642
18	200 bp, 390 bp	1070 bp	A24, A31, A32, A33, A68, A74	*02:243:01-02:243:03, 02:929, 24:82, 26:177, 26:207, 29:48, 29:105, 29:164, 31:08, 31:109, 32:05, 32:15, 32:79, 32:93, 33:01:01:01-33:01:18, 33:03:01:01-33:37, 33:39-33:234, 68:29, 68:250, 74:04, 74:21, 74:43
19	370 bp	800 bp	A2, A19, A68, A74	*01:121, 02:65, 02:407, 02:449, 02:932, 03:246, 03:282, 11:07:02, 11:372, 68:25, 68:262, 74:01:01:01-74:44
20^{10,11}	210 bp, 240 bp	800 bp	A2, A25, A28, A68	*02:34-02:35:03, 02:46, 02:48, 02:56:01-02:56:02, 02:62, 02:70, 02:78, 02:103, 02:129, 02:571, 02:580, 02:651, 02:741, 02:907, 02:1050, 11:199:03, 25:05, 25:59, 26:54, 26:122, 26:229, 68:01:01:01-68:217, 68:219-68:257, 68:259-68:298
21⁵	65 bp, 240 bp, 375 bp, 545 bp	800 bp	A2, A26, A28, A32, A66, A68, A69	*02:55, 02:149:01-02:149:02, 02:243:01-02:243:03, 02:309, 02:644, 02:741, 02:815, 02:842, 02:947, 23:57, 24:82, 25:30, 26:22, 26:177, 29:80, 29:155, 31:41, 32:06, 33:22, 66:06, 66:09, 68:08:02, 68:29, 68:105:01:01-68:105:01:02, 68:157, 68:250, 68:276Q, 69:01:01:01-69:09, 74:35
22^{5,8}	85 bp, 240 bp, 400 bp	800 bp	A2, A36	*01:427, 02:34-02:35:03, 02:46, 02:48, 02:56:01-02:56:02, 02:62, 02:70, 02:78, 02:103, 02:129, 02:571, 02:576, 02:580, 02:682, 02:741, 02:907, 02:1050, 03:187, 11:155, 11:199:03, 11:226, 31:62, 34:22, 36:01:01:01-36:13, 68:11N, 68:41, 68:230, B*07:439, B*35:491, B*40:359, B*55:96, B*57:65, C*04:31, C*06:137, C*07:569, C*07:990, C*07:994



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

23^{5,10}	80 bp, 160 bp, 240 bp, 495 bp	800 bp	A2, A3, A24, A26, A28, A36, A68, A80	*01:427, 02:55, 02:237, 02:671, 02:809, 02:927, 03:41, 03:63, 03:75, 03:88, 03:95, 03:177, 03:343, 03:347, 03:377, 03:382, 11:130, 24:18, 24:204, 24:213, 26:03:01:01-26:03:01:02, 26:03:03, 26:05- 26:06, 26:21, 26:30, 26:78, 26:111, 26:177, 26:227, 26:229, 33:24, 33:184, 36:02, 68:05, 68:15, 68:20, 68:109, 68:136, 68:255, 80:01:01:01-80:01:02, 80:03-80:09N, C*06:187
24^{9,11}	360 bp, 445 bp	1070 bp	A10, A26, A31, A66	*02:135, 02:309, 02:454, 03:01:19, 03:103:02, 25:13, 25:46, 25:82-25:83, 26:07:01-26:07:02, 26:30, 26:65, 26:92, 31:04:01:01-31:04:02, 31:123, 34:09, 66:02:01:01-66:03:01:03, 66:12, 66:16, 66:21, 66:25-66:26Q, 66:28N, 66:34, 66:39N, 66:42-66:43, 68:294, 74:01:03
25	190 bp, 400 bp	1070 bp	A24, A29, A30, A31, A32, A33, A74	*02:929, 11:306, 26:207, 29:01:01:01-29:01:14, 29:02:01:01-29:29, 29:31-29:118, 29:120-29:140, 29:142-29:154, 29:156-29:172, 30:01:01:01- 30:01:07, 30:01:09-30:04:04, 30:06-30:11:02, 30:13-30:17, 30:19-30:20, 30:22-30:30, 30:32- 30:40, 30:42-30:54, 30:56-30:59N, 30:61-30:102, 30:104-30:151, 30:153-30:165, 30:167-30:206, 31:01:02:01-31:08, 31:10-31:27, 31:29-31:219, 32:01:01:01-32:03:01:02, 32:05-32:23, 32:25- 32:48N, 32:50-32:115, 32:117N-32:173, 33:01:01:01-33:01:18, 33:03:01:01-33:37, 33:39- 33:162, 33:164-33:184, 33:186-33:234, 74:01:01:01-74:44
26	195 bp, 225 bp	800 bp	A1, A36, A43	*01:01:01:01-01:04:01:02N, 01:07-01:11N, 01:13, 01:16N-01:18N, 01:21-01:33, 01:35-01:52:02N, 01:54-01:62, 01:64, 01:67:01-01:72, 01:74-01:97, 01:99-01:126, 01:128-01:129, 01:131-01:135, 01:137-01:199, 01:201-01:221, 01:223-01:243, 01:245-01:254, 01:256-01:300, 01:301Q*, 01:302- 01:343, 01:345-01:359, 01:361N-01:379N, 01:381-01:390, 01:392-01:426, 03:18, 03:135, 11:11, 11:94, 11:112, 11:211, 11:226, 11:271, 11:290, 11:326, 25:59, 31:200, 36:04, 43:01- 43:03, 68:130:01
27^{9,11}	205 bp	1070 bp	A1, A3, A11, A30, A31, A32, A34	*01:12, 01:19, 01:21, 01:126, 01:200, 01:244, 01:360, 02:156, 02:338, 02:952, 03:01:01:01- 03:01:05, 03:01:07-03:01:13, 03:01:15-03:01:46, 03:01:48, 03:01:50-03:01:51, 03:01:53-03:17:02, 03:19-03:49, 03:51:01-03:53, 03:55-03:63, 03:65- 03:68N, 03:70-03:74, 03:76-03:94, 03:96-03:126, 03:128-03:134, 03:136-03:139, 03:141-03:152, 03:154:01-03:164, 03:166-03:176, 03:178N- 03:186, 03:188-03:193, 03:195-03:199, 03:201- 03:203, 03:205-03:214, 03:216-03:230, 03:232- 03:233, 03:235-03:248, 03:250-03:259, 03:261- 03:287, 03:289:01-03:321, 03:323N-03:342N, 03:344:01-03:346, 03:348-03:376, 03:378-03:413, 03:415, 03:417-03:458Q, 11:03:01:01- 11:03:01:02, 11:08, 11:20, 11:25:01-11:25:03,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

				11:31, 11:35, 11:60, 11:158, 11:175, 11:183, 11:209, 11:348, 11:366, 11:381, 24:92, 24:458, 24:551, 24:557, 30:04:01:01-30:04:04, 30:06, 30:09:01:01-30:09:01:02, 30:17, 30:29, 30:46, 30:77, 30:89-30:90, 30:99, 30:103, 30:105, 30:117, 30:139, 30:150, 30:155, 30:160, 30:183, 31:03-31:04:02, 31:176, 31:179, 32:04, 33:49, 33:144, 34:02:01:01-34:04, 34:07-34:10N, 34:13, 34:15, 34:20-34:22, 34:24-34:26N, 34:28-34:30N, 68:103:01-68:103:02, 74:23
28^{5,9,11}	100 bp, 520 bp	1070 bp	A1, A2, A3, A9, A11, A23, A24, A28, A29, A30, A66, A68, A69	*01:13, 01:17, 01:176, 01:194, 01:302, 02:34-02:35:03, 02:56:01-02:56:02, 02:62, 02:78, 02:103, 02:580, 02:907, 03:01:01:01-03:07:02, 03:09-03:31, 03:33, 03:35, 03:37-03:40, 03:42-03:61, 03:64-03:87, 03:90-03:106, 03:109-03:151, 03:153-03:171, 03:173-03:175, 03:177-03:193, 03:195-03:197:02N, 03:199, 03:201-03:259, 03:261-03:262N, 03:264-03:272, 03:274-03:381N, 03:383-03:397, 03:399-03:412, 03:414-03:446, 03:448N-03:450, 03:452-03:458Q, 11:12:01, 11:155, 11:226, 11:271, 11:326, 23:13, 24:07:01:01-24:07:04, 24:24, 24:108, 24:112, 24:131, 24:288, 24:290, 24:294Q, 24:339, 24:347:01-24:347:02, 24:387, 24:406, 24:453, 24:457, 24:477, 24:489, 24:510, 24:528, 24:541, 24:544, 24:566, 24:569, 24:574, 29:01:01:01-29:18, 29:21-29:29, 29:31-29:33, 29:35-29:47, 29:49-29:65, 29:67-29:73, 29:75-29:97, 29:99-29:105, 29:107-29:140, 29:142-29:172, 30:01:01:01-30:01:21, 30:08:01-30:08:02, 30:11:01-30:11:02, 30:14L-30:20, 30:23-30:26, 30:30, 30:35-30:43, 30:48-30:49, 30:52-30:56, 30:58-30:60, 30:62-30:63, 30:65, 30:71-30:75, 30:78N-30:79, 30:81-30:83, 30:86-30:89, 30:91-30:98, 30:102, 30:104, 30:106, 30:109-30:116, 30:118, 30:120, 30:122-30:123N, 30:126, 30:128-30:132N, 30:134-30:138, 30:141-30:143, 30:145N, 30:147-30:148, 30:154, 30:159, 30:161, 30:163-30:165, 30:167-30:168, 30:170-30:173, 30:176, 30:178N-30:181, 30:183-30:187, 30:190-30:192, 30:194-30:197N, 30:199, 30:201-30:203, 30:205, 31:89, 31:115, 32:17, 33:125, 33:131, 34:09, 66:02:01:01-66:02:01:03, 66:12, 66:16, 66:21, 66:25-66:26Q, 66:34, 66:43, 68:01:01:01-68:01:17, 68:01:19-68:01:56, 68:01:58-68:02:19, 68:02:21-68:02:22, 68:06-68:14, 68:16-68:19, 68:21:01-68:30, 68:32-68:71, 68:73-68:89, 68:91-68:92, 68:94N-68:96, 68:98-68:108, 68:110-68:179, 68:181N-68:205N, 68:207-68:211, 68:213N-68:226, 68:228-68:248, 68:250-68:254, 68:256-68:298, 69:01:01:01-69:01:04, 69:03-69:07, 69:09, 74:13, 74:42
29^{5,11}	105 bp, 260 bp	800 bp	A3, A11, A26, A30, A68, A74	*01:134, 01:229, 03:09, 03:89:02, 03:108, 03:172, 03:198, 03:330N, 11:06, 11:18, 11:312, 24:09N,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

				26:03:01:01-26:03:01:02, 26:03:03, 26:06, 26:21, 26:30, 26:78, 26:92, 26:111, 26:177, 26:193, 26:227, 26:229, 29:19, 29:48, 29:159, 30:13, 30:16, 30:44, 30:46, 33:24, 33:184, 68:05, 68:15, 68:20, 68:255, 74:06, 74:21, 74:39, C*06:247
30^{10,12}	180 bp, 465 bp	1070 bp	A10, A25, A26, A43, A66	*01:01:56, 01:04:01:01N-01:04:01:02N, 02:135, 03:21N, 11:21N, 23:07N, 24:11N, 25:01:01:01-25:01:08, 25:01:10-25:01:16, 25:01:18-25:05, 25:07-25:17, 25:19:01-25:35, 25:37-25:42N, 25:44-25:49N, 25:51, 25:53-25:58, 25:60-25:84, 26:01:01:01-26:01:20, 26:01:22-26:01:58, 26:01:60-26:03:01:02, 26:05-26:08:01:03, 26:08:03, 26:10-26:33, 26:35-26:43:02, 26:45-26:72, 26:74-26:77, 26:79-26:90, 26:92-26:102, 26:104-26:203, 26:206:01N-26:229, 30:132N, 43:01-43:03, 66:01:01:01-66:01:01:06, 66:01:03-66:01:07, 66:04-66:15, 66:17-66:20, 66:22-66:24, 66:27N, 66:29-66:33, 66:35-66:38, 66:41-66:42, 66:44-66:47
31⁵	110 bp, 195 bp, 465 bp	1070 bp	A34	*01:04:01:01N-01:04:01:02N, 02:741, 03:21N, 03:248, 11:21N, 11:191, 11:404, 23:07N, 24:11N, 25:43, 30:132N, 34:01:01:01-34:02:07, 34:04-34:05, 34:07-34:18, 34:20-34:21, 34:23-34:30N
32¹³	-	-	-	Negative control

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-A low resolution SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length. Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³The serological reactivity of all HLA-A alleles is not known. In this table we use the expert-assigned serological grouping in Tissue Antigens (2009) 73:95-170 and the serological grouping of the sequence-defined allele.

⁴For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 9R2

Lot-specific information

⁵HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

⁶Primer mix 6 may give rise to a lower yield of A*23 alleles than the other A low primer mixes.

⁷Primer mix 9 may weakly amplify the A*34 alleles.

⁸Primer mix 22 might faintly amplify most A*11 alleles.

⁹Primer mixes 15, 24, 27 and 28 may give rise to a lower yield of HLA-specific PCR product than the other HLA-A low primer mixes.

¹⁰Primer mixes 6, 10, 14, 20, 23 and 30 have a tendency to giving rise to primer oligomer formation.

¹¹Primer mixes 13, 15, 17, 20, 24 and 27 to 29 may have tendencies of unspecific amplifications.

¹²Primer mix 30 may generate a false positive band of about 500 base pairs. This band should be disregarded when interpreting HLA-A low resolution typings.

¹³Primer mix 32 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

w: might be weakly amplified.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec.	120	135	235	190	160	135	175	165	80	80	80	125
PCR product	145	175			335	200	205	200		200	175	160
		215			505					240	500	190
		255										
		365										
		415										
Length of int.	800	800	1070	800	1070	800	1070	800	800	800	1070	800
pos. control ¹												
5'-primer(s) ²	98	48	363	98	144	176	98	98	257	98	301	103
	5'-CTT 3'	5'-gCT 3'	5'-ATA 3'	5'-CTA 3'	5'-gCC 3'	5'-gCA 3'	5'-CTC 3'	5'-CTA 3'	5'-Cgg 3'	5'-CTA 3'	5'-Cgg 3'	5'-CCT 3'
	103	78		413	317	368	368	102	259	261	302	415
	5'-CCT 3'	5'-TCT 3'		5'-CCg 3'	5'-gCT 3'	5'-gTT 3'	5'-gTT 3'	5'-ACA 3'	5'-AgA 3'	5'-AAC 3'	5'-ggA 3'	5'-ggT 3'
	123	106						413	261		385	423
	5'-AgT 3'	5'-CCA 3'						5'-CCg 3'	5'-AAC 3'		5'-ggC 3'	5'-gCT 3'
		144							266			
		5'-gCA 3'							5'-ACg 3'			
3'-primer(s) ³	203	240	555	256	265	270	259	259	302	256	341	257
	5'-TCT 3'	5'-ggA 3'	5'-gCA 3'	5'-CTg 3'	5'-CCC 3'	5'-ACA 3'	5'-gTT 3'	5'-gTT 3'	5'-ggC 3'	5'-CCA 3'	5'-CgT 3'	5'-gCA 3'
		292	555	559	368	521	502	259	303	299	521	506
		5'-gTg 3'	5'-CCA 3'	5'-CCg 3'	5'-CAA 3'	5'-ggg 3'	5'-CTT 3'	5'-gTT 3'	5'-AgA 3'	5'-TCg 3'	5'-ggg 3'	5'-TgT 3'
						526	539	538		300		538
						5'-CCg 3'	5'-TCT 3'	5'-CCA 3'		5'-TTT 3'		5'-CCg 3'
						534				308		559
						5'-CgT 3'				5'-TCT 3'		5'-CTC 3'
												559
												5'-CgT 3'
												559
												5'-CgC 3'
												563
												5'-CgA 3'
Well No.	1	2	3	4	5	6	7	8	9	10	11	12



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec.	180	80	90	145	140	200	370	210	65	85	80	360
PCR product	225	115	135	240	180	390		240	240	240	160	445
		200	205	380	240				375	400	240	
		240		410	260				545		495	
		460										
Length of int.	1070	1070	1070	1070	1070	1070	800	800	800	800	800	1070
pos. control ¹												
5'-primer(s) ²	98	98	203	41	98	41	302	78	28	47	176	257
	5'-CTT 3'	5'-CAC 3'	5'-gAA 3'	5'-CTT 3'	5'-CTT 3'	5'-CTT 3'	5'-ggA 3'	5'-TCT 3'	5'-TCg 3'	5'-g.T 3'	5'-gCA 3'	5'-Cgg 3'
	414	219	362	160	180	98	302	106	261	78	261	341
	5'-CAg 3'	5'-gCA 3'	5'-ggT 3'	5'-ACg 3'	5'-TTT 3'	5'-CAC 3'	5'-ggA 3'	5'-CCA 3'	5'-AAC 3'	5'-TCT 3'	5'-AAC 3'	5'-ggC 3'
	423	238	363	355	203		317	2 nd I	502	521	341	
	5'-gCT 3'	5'-AgA 3'	5'-ATA 3'	5'-CCg 3'	5'-gAA 3'		5'-gCg 3'	5'-CCT 3'	5'-CCC 3'	5'-ggT 3'	5'-ggA 3'	
		355	363		418			2 nd I		527	355	
		5'-CCg 3'	5'-ATA 3'		5'-AgC 3'			5'-ggC 3'		5'-TgC 3'	5'-CCC 3'	
		489	363								362	
		5'-gCA 3'	5'-ATA 3'								5'-gAg 3'	
			369								362	
			5'-TAC 3'								5'-gAg 3'	
3'-primer(s) ³	282	180	299	238	290	256	397	265	97	265	292	418
	5'-gAC 3'	5'-TCA 3'	5'-CCA 3'	5'-CCT 3'	5'-CAA 3'	5'-CCC 3'	5'-gAg 3'	5'-CCC 3'	5'-ggT 3'	5'-CCC 3'	5'-gTg 3'	5'-gTC 3'
	282	257	411	238	299	259		282	355	282	292	
	5'-gAC 3'	5'-gCA 3'	5'-TCA 3'	5'-CCT 3'	5'-TCT 3'	5'-gTT 3'		5'-gAC 3'	5'-gAC 3'	5'-gAC 3'	5'-gTT 3'	
	559	418	526	243	317	261		282	524	282	299	
	5'-CCC 3'	5'-gTC 3'	5'-CCA 3'	5'-TCA 3'	5'-ggA 3'	5'-gTg 3'		5'-gAC 3'	5'-CAT 3'	5'-gAC 3'	5'-TCT 3'	
	560	555		265	555	265		502		570	555	
	5'-ACC 3'	5'-CCA 3'		5'-CCC 3'	5'-CCA 3'	5'-CCC 3'		5'-CTT 3'		5'-CAC 3'	5'-CCA 3'	
				282		265		506				
				5'-gAC 3'		5'-CCC 3'		5'-TgT 3'				
				555		265						
				5'-CCA 3'		5'-CCA 3'						
Well No.	13	14	15	16	17	18	19	20	21	22	23	24

Well No.	25	26	27	28	29	30	31
Length of spec.	190	195	205	100	105	180	110
PCR product	400	225		520	260	465	195
							465
Length of int.	1070	800	1070	1070	800	1070	1070
pos. control ¹							
5'-primer(s) ²	41	103	363	282	74	418	270
	5'-CTT 3'	5'-CCT 3'	5'-ATA 3'	5'-CAg 3'	5'-C 3'	5'-AgA 3'	5'-AAA 3'
	123	363		282	78	423	363
	5'-AgT 3'	5'-ATA 3'		5'-CAg 3'	5'-TCC 3'	5'-gCT 3'	5'-ATA 3'
		363			678	3 rd I	3 rd I
		5'-ATg 3'			5'-AgA 3'	5'-A 3'	5'-A 3'
3'-primer(s) ³	270	257	527	341	292	559	341
	5'-ACT 3'	5'-gCA 3'	5'-CCA 3'	5'-Cgg 3'	5'-gTg 3'	5'-CCg 3'	5'-CgT 3'
	270	545	527	521	742	559	517
	5'-ACA 3'	5'-AgA 3'	5'-CCT 3'	5'-ggA 3'	5'-CTA 3'	5'-CCg 3'	5'-CgT 3'
			527			621	621
			5'-CCT 3'			5'-ggg 3'	5'-ggg 3'
Well No.	25	26	27	28	29	30	31



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 9R2

Lot-specific information

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A low resolution primer set ²																				
					Well															
				Prod No.:	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
					202351017	202348618	202348619	202348620	202348621	202348622	202348623A	202348624	201907925	202018326	201907927	201907928	202244229	201907930	201907931	
	IHWC cell line ¹	A*	A*																	
1	9001 SA	*24:02			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01			-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
4	9275 GU373	*30:01			-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	
5	9009 KAS011	*01:01			-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
6	9353 SM	*02:01	*26:03		-	-	-	-	-	-	+	-	-	-	-	-	+	+	-	
7	9020 QBL	*26:01			-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	
8	9025 DEU	*31:01			-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	
9	9026 YAR	*26:01			-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	
10	9107 LKT3	*24:02			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02			-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	
12	9052 DBB	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01			-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	
15	9075 DKB	*24:02			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02			-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	
17	9282 CTM3953540	*03:01	*80:01		-	-	-	-	-	-	+	-	-	-	+	+	-	-	-	
18	9257 32367	*33:03	*74:01		-	+	+	-	-	-	-	-	+	-	-	-	-	-	-	
19	9038 BM16	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
24	9035 JBUSH	*32:01			+	-	-	-	-	-	-	-	+	-	-	-	-	-	-	
25	9049 IBW9	*33:01			-	+	-	-	-	-	-	-	+	-	-	-	-	-	-	
26	9285 WT49	*02:05			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01		-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	
28	9320 BEL5GB	*02:01	*29:02		-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	
29	9050 MOU	*29:02			-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	
30	9021 RSH	*30:01	*68:02		-	-	-	+	-	-	-	-	+	-	-	+	-	-	-	
31	9019 DUCAF	*30:02			-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	
32	9297 HAG	*02:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01			-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	
34	9104 DHIF	*31:01			-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	
35	9302 SSTO	*32:01			+	-	-	-	-	-	-	-	+	-	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01			-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	
38	9099 LZL	*02:17			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01		-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	
40	9134 WHONP199	*02:07	*30:01		-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	
41	9055 H0301	*03:01			-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	
42	9066 TAB089	*02:07			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01			-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	
45	9239 SHJO	*23:01	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU	*03:01			-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	
47	9045 TUBO	*02:16	*03:01		-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	
48	9303 TER-ND	*02:01	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 9R2

Lot-specific information

¹The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

²The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

One or more 5'- and 3'-primers in primer solutions 4, 5, 7, 8, 12, 14 to 17, 20 to 23, 26, 30 and 31 were tested by separately adding one or more 3'-primers, and one or more 5'-primers, respectively. One or more 5'-primers in primer solutions 1, 2, 9, 13 and 24 were tested by separately adding one or two 3'-primers. One or more 3'-primers in primer solutions 10, 18 and 27 were tested by separately adding one 5'-primer.

In primer solutions 2, 9, 11, 12, 15, 20, 22 and 29 one or two 5'-primers were not possible to be tested, and in primer solutions 3, 6, 8, 9, 10, 12, 13, 16 and 18 one or two 3'-primers were not possible to be tested.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: October 2025, Rev. No: 01

101.401-48/12 – including *Taq* polymerase
101.401-48u/12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **9R2**

Lot-specific information

ADDRESSES:

Manufacturer:

CareDx AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

Fax: +46-8-717 88 18

E-mail: orders-se@caredx.com

Web page: www.caredx.com

CareDx Lab Solutions Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-653-78171

Fax: 610-344-7989

E-mail: orders-us@caredx.com

Web page: www.caredx.com

For information on CareDx distributors worldwide, contact **CareDx AB**.



0197

For *In Vitro* Diagnostic Use

MA123 v02 SSP PI Template

Date: October 2025, Rev. No: 01